Please select the option that best describes you:

How do you sequence abiraterone and enzalutamide in metastatic, castrate-resistant prostate cancer?   

What determines which you select first? How do concerns about cross-resistance factor in after progression on one of these agents?



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more